肝硬化心肌病影响慢加急性肝衰竭合并严重脓毒症患者的临床结局并提升传统风险预测模型效能
本研究对120例慢加急性肝衰竭合并脓毒症诱导低血压患者进行系列床旁超声心动图检查,评估心脏指数、全身血管阻力指数及肝硬化心肌病标志物与循环衰竭和死亡的关系。结果显示肝硬化心肌病标志物及心脏指数变化可预测循环衰竭和死亡,且将标志物纳入MELDNa和CLIF-C ACLF评分后预测90天死亡效能优于原模型。
要点
- 肝硬化心肌病标志物E/e'和e'速度及心脏指数变化可预测慢加急性肝衰竭合并严重脓毒症患者的循环衰竭和死亡。
- 72小时心脏指数降低20%和全身血管阻力指数降低15%预测死亡的敏感度分别为84%和72%,特异度分别为76%和65%。
- MELD-CCM和CLIF-CCM模型预测90天死亡优于MELDNa和CLIF-C ACLF评分。
核心结论
- 床旁超声心动图测量的肝硬化心肌病标志物(E/e'和e'速度)及心脏指数变化可可靠预测慢加急性肝衰竭合并严重脓毒症患者的循环衰竭和死亡。
- 肝硬化心肌病标志物显著提升了CLIF-C ACLF和MELDNa的预测效能。
研究设计与样本
- 研究纳入120例入住肝病重症监护室的慢加急性肝衰竭合并脓毒症诱导低血压患者,其中男性59%,年龄49±12岁,酒精相关疾病56%,MELDNa中位数30(27-32)。
- 在就诊6小时内及后续24、48、72小时进行系列床旁超声心动图检查,前瞻性收集临床数据、床旁超声数据和血清生物标志物。
主要发现
- 68例(56.6%)发生循环衰竭,总死亡率为60%,52.5%存在肝硬化心肌病。
- 循环衰竭的预测因素包括心脏指数(aHR -1.5;p=0.021)、N末端脑钠肽前体(aHR -1.1;p=0.007)及肝硬化心肌病标志物:室间隔二尖瓣e'速度(aHR -0.5;p=0.039)和E/e'比值(aHR -1.2;p=0.045)。
- 72小时心脏指数降低20%预测死亡的敏感度为84%、特异度为76%,全身血管阻力指数降低15%预测死亡的敏感度为72%、特异度为65%(p<0.001)。
- MELD-CCM模型和CLIF-CCM模型预测90天死亡分别优于MELDNa(z-score=-2.073,p=0.038)和CLIF-C ACLF评分(z-score=-2.683,p=0.007)。
关键数值与推荐
- MELD-CCM模型计算为MELDNa + 1.815 × E/e'(室间隔)+ 0.402 × e'(室间隔)。
- CLIF-CCM模型计算为CLIF-C ACLF + 1.815 × E/e'(室间隔)+ 0.402 × e'(室间隔)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Point-of-care echocardiography (POC-Echo) is an essential intensive care hemodynamic monitoring tool. AIMS: To assess POC-Echo parameters [i.e., cardiac index (CI), systemic vascular resistance index (SVRI) and cirrhotic cardiomyopathy (CCM) markers] and serum biomarkers in predicting circulatory failure (need for vasopressors) and mortality in patients with acute-on-chronic liver failure (ACLF) having sepsis-induced hypotension. METHODS: We performed serial POC-Echo within 6 hours (h) of presentation and subsequently at 24, 48 and 72 h in patients with ACLF and sepsis-induced hypotension admitted to our liver intensive care unit. Clinical data, POC-Echo data and serum biomarkers were collected prospectively. RESULTS: We enrolled 120 patients [59% men, aged 49 ± 12 years, 56% alcohol-related disease and median MELDNa of 30 (27-32)], of whom 68 (56.6%) had circulatory failure, with overall mortality of 60%. CCM was present in 52.5%. The predictors of circulatory failure were CI (aHR -1.5; p = 0.021), N-terminal brain natriuretic peptide (aHR -1.1; p = 0.007) and CCM markers; e' septal mitral velocity (aHR -0.5; p = 0.039) and E/e' ratio (aHR -1.2; p = 0.045). Reduction in CI by 20% and SVRI by 15% at 72 h predicted mortality with a sensitivity of 84% and 72%, and specificity 76% and 65%, respectively (p < 0.001). The MELD-CCM model and CLIF-CCM model were computed as MELDNa + 1.815 × E/e' (septal) + 0.402 × e' (septal) and CLIF-C ACLF + 1.815 × E/e' (septal) + 0.402 × e' (septal), respectively, based on multivariable logistic regression. Both scores outperformed MELDNa (z-score = -2.073, p = 0.038) and CLIF-C ACLF score (z score = -2.683, p-value = 0.007), respectively, in predicting 90-day mortality. CONCLUSION: POC-Echo measurements such as CCM markers (E/e' and e' velocity) and change in CI reliably predict circulatory failure and mortality in ACLF with severe sepsis. CCM markers significantly enhanced the CLIF-C ACLF and MELDNa predictive performance.
引用
- Kajal K, Premkumar M, Izzy M, et al. Cirrhotic cardiomyopathy influences clinical outcomes and enhances performance of conventional risk prediction models in acute-on-chronic liver failure with severe sepsis. Aliment Pharmacol Ther. 2023. PMID: 37688403. doi:10.1111/apt.17695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。